Jones Trading upgraded shares of Nuvation Bio (NYSE:NUVB - Free Report) to a strong-buy rating in a research report sent to investors on Tuesday, March 11th, MarketBeat reports.
Several other research analysts have also weighed in on the company. Wedbush reaffirmed an "outperform" rating and set a $5.00 price target on shares of Nuvation Bio in a research report on Monday, March 3rd. HC Wainwright reduced their target price on Nuvation Bio from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, March 10th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 target price (up from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $8.33.
Read Our Latest Stock Report on Nuvation Bio
Nuvation Bio Trading Down 6.0 %
Shares of NYSE:NUVB traded down $0.13 during trading on Tuesday, hitting $1.97. 2,142,475 shares of the company were exchanged, compared to its average volume of 1,960,576. The stock has a market cap of $665.50 million, a price-to-earnings ratio of -0.91 and a beta of 1.47. Nuvation Bio has a fifty-two week low of $1.67 and a fifty-two week high of $4.16. The firm has a fifty day moving average price of $2.34 and a two-hundred day moving average price of $2.54.
Institutional Trading of Nuvation Bio
Institutional investors have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC bought a new stake in Nuvation Bio in the 4th quarter valued at $27,000. Forum Financial Management LP bought a new stake in Nuvation Bio in the 4th quarter valued at $29,000. Cerity Partners LLC bought a new stake in Nuvation Bio in the 4th quarter valued at $31,000. Russell Investments Group Ltd. boosted its stake in Nuvation Bio by 15,183.7% in the 4th quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company's stock valued at $42,000 after purchasing an additional 15,791 shares during the period. Finally, Abacus Planning Group Inc. bought a new stake in Nuvation Bio in the 4th quarter valued at $44,000. 61.67% of the stock is currently owned by institutional investors.
Nuvation Bio Company Profile
(
Get Free Report)
Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.
Featured Stories
Before you consider Nuvation Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvation Bio wasn't on the list.
While Nuvation Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
